PepGen prices $125 million public stock offering at $5 per share

PepGen Inc. announced that it priced a public offering of 25 million common shares at $5.00 each, generating $125 million in gross proceeds. The company granted underwriters a 30‑day option to purchase an additional 3.75 million shares, potentially adding $18.75 million to the raise. Net proceeds are earmarked for clinical development of its myotonic dystrophy candidate, working capital and other corporate purposes. Joint bookrunners for the transaction are Leerink Partners, Stifel and Guggenheim Securities.

The capital infusion will fund PepGen’s ongoing clinical program and support its operating needs, reducing financing risk for the biotech. The additional over‑allotment option could increase total proceeds to $143.75 million if exercised.

  • 1PepGen launched a public offering of $125.0 million of common stock and pre‑funded warrants.
  • 2Underwriters have a 30‑day option to purchase up to an additional $18.75 million of shares at the offering price.
  • 3The offering was priced at $5.00 per share for 25 million shares, raising $125 million before costs.
  • 4The underwriters’ option covers 3.75 million additional shares.
  • 5Joint bookrunners are Leerink Partners, Stifel and Guggenheim Securities.
  • 6PepGen intends to use net proceeds for clinical development of PGN‑EDODM1, working capital and other corporate purposes.

Sources